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Abstract: Appropriate tools are necessary for predicting cardiovascular events in patients with 
diabetes mellitus because of their high incidence. In this study, we assessed whether a combina-
tion of brain natriuretic peptide (BNP) and C-reactive protein (CRP) measurement were useful 
prognosticators in patients with type 2 diabetes mellitus. One hundred and nine patients with 
type 2 diabetes mellitus, aged 52 to 93 years, were examined at outpatient clinics for blood, uri-
nary samples, and echocardiography. They were then followed prospectively. During the average 
follow-up period of 30 months (range, 3 to 37), 15 patients (14%) had cardiovascular events: 
This was the ﬁ  rst event in 5 patients and a recurrence in 10. Cox regression analysis showed 
that the past event (hazard ratio [HR] 4.819 [95% conﬁ  dence interval (CI): 1.299–17.881]; 
p = 0.019) and plasma BNP level (HR 1.007 [95% CI: 1.002–1.012]; p = 0.010] were indepen-
dently signiﬁ  cant factors for the cardiovascular events during the follow-up period. Patients 
with plasma BNP 53 pg/mL and CRP 0.95 mg/dL demonstrated the highest incidence in 
cardiovascular event, compared to those categorized into either or both low levels of BNP and 
CRP. This study suggests that combination of plasma BNP and CRP measurement provides 
the additive prognostic information of cardiovascular events in patients with type 2 diabetes 
mellitus.
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Introduction
Cardiovascular disease is the leading cause of morbidity and mortality in diabetic 
patients (ADA et al 1999). Diabetes mellitus has been reported to be associated with 
coronary artery disease, left ventricular (LV) hypertrophy, and systolic and/or diastolic 
dysfunction (Poirier et al 2001). A recent study showed that 14% of patients with type 
2 diabetic mellitus develop congestive heart failure (Nichols et al 2004). Accordingly, 
the risk of cardiovascular diseases in diabetic patients is two- to three-fold that among 
non-diabetic population (Garcia et al 1974). As the symptoms diabetic patients complain 
of are often discordant with the severity of myocardial ischemia and dysfunction, we 
need reliable screening methods for cardiac function and for predicting cardiovascular 
events to reduce the morbidity and mortality (Janand-Delenne et al 1999; Struthers 
and Morris 2002; Fang et al 2005).
Brain natriuretic peptide (BNP), a 32-amino-acid hormone, is synthesized mainly 
in the cardiac myocardium in response to ventricular dilation and pressure overload 
(Yoshimura et al 1993; Maeda et al 1998). The plasma levels of BNP are elevated 
in patients with congestive heart failure in proportion to the degree of LV dysfunc-
tion and the severity of symptoms (Tsutamoto et al 1997). In addition, the plasma 
level of BNP has been reported to independently predict cardiovascular events and 
death, even in patients without heart failure (de Lemos et al 2001; Wang et al 2004). Vascular Health and Risk Management 2007:3(4) 418
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Thus, measuring the plasma BNP concentration has been 
recognized as clinically useful for screening the heart dis-
eases with a cost beneﬁ  t value (Ogawa et al 2002). C-reac-
tive protein (CRP), an acute phase reactant produced in the 
liver, is increased in inﬂ  ammatory states. Epidemiological 
studies have shown that minor CRP elevation is associ-
ated with the major cardiovascular risk (Ridker et al 2000; 
Danesh et al 2004; Wakugawa et al 2006) and lowering of 
CRP levels by pharmacological intervention is beneﬁ  cial for 
the secondary prevention of coronary artery disease (Ridker 
et al 2005). Furthermore, accumulating evidence suggests a 
link between hyperglycemia and inﬂ  ammation in diabetic 
patients (Schulze et al 2004).
Although BNP and CRP measurements are recognized 
for their usefulness for detecting and predicting cardio-
vascular events, their utility has not reached its maximum 
potential. Therefore, we hypothesized whether the blood 
levels of the two molecules provide the additive value for 
predicting cardiovascular events in patients with type 2 
diabetes mellitus.
Methods
Study population
This study was approved by the Human Investigation Review 
Committee of the University of Miyazaki (No. 126) and 
conformed with the principles outlined in the Declaration of 
Helsinki (Cardiovasc Res 1997; 35: 2–4). Written informed 
consent was obtained from all participants. One hundred and 
nine patients with type 2 diabetes mellitus (71 ± 10 years old; 
male, 50%) were recruited from November 2003 to May 2005 
at the outpatient clinics of University of Miyazaki and af-
ﬁ  liated hospitals. The cardiologists examined whether they 
had cardiovascular diseases such as coronary artery disease, 
heart failure, stroke and transient ischemia attack. Out of 109 
patients, 29 of them had the cardiovascular disease; 11 stroke, 
2 transient ischemia attack, 3 angina pectoris, 6 myocardial 
infarction, and 7 patients had congestive heart failure. All 
patients had been stable within 3 months prior to entry of 
this study. Diabetes mellitus was deﬁ  ned according to the 
statement of the American Diabetes Association: fasting 
plasma glucose level 126 mg/dL, two-hour postprandial 
glucose 200 mg/dL, or receiving any antidiabetes medicine. 
Hypertension was deﬁ  ned as systolic blood pressure 140 
mmHg, diastolic blood pressure 90 mm Hg or taking any 
antihypertensive medicine and hyperlipidemia as fasting 
plasma cholesterol level 220 mg/dL, triglyceride 150 
mg/dL, or taking any medicine for hyperlipidemia. Insulin 
resistance was assessed by the homeostasis model assessment 
(HOMA)-R index calculated using the formula of fasting 
serum insulin (mU/L) × fasting plasma glucose (mg/dL)/405. 
Subjects with inﬂ  ammatory diseases such as infection or 
rheumatoid arthritis were excluded from this study. 
Laboratory parameters
All samples were obtained at the outpatient clinics in the 
morning. At initial evaluations, 5 ml of blood sample was 
collected with EDTA-2Na (1.5 mg/mL blood). Plasma BNP 
levels were measured using an immunoradiometric assay 
or chemiluminescence enzyme immunoassay (Shionoria 
BNP or MI02 Shionogi BNP; Shionogi Inc., Osaka, Japan); 
identical values of BNP levels were obtained by these two 
methods (r = 0.981). Serum levels of CRP were determined 
by the latex agglutination test with a measurement range of 
0.01 to 40 mg/dL. The level of HbA1c was measured by the 
immuno-turbidimetric method or high performance liquid 
chromatography (ARKRAY HA-8160), and total choles-
terol and triglyceride by an enzymatic method. The ﬁ  rst, 
morning-voided urine was collected and the urinary level of 
albumin was analyzed by immuno-turbidity method using an 
anti-human albumin antibody.
Echocardiography
Two-dimensional, M-mode and color ﬂ  ow Doppler echo-
cardiograms were obtained with an instrument operating 
at 2.5 MHz. Two-dimensional imaging was performed in 
a standard fashion with the parasternal long- or short-axis 
and apical two- or four-chamber views. Left atrial and LV 
end-diastolic or systolic dimensions were obtained by an 
M-mode view. After careful analysis of regional contractile 
abnormalities, LV ejection fraction was determined by either 
biplane apical views with a modiﬁ  ed Simpson’s method or 
the formula of (LV end-diastolic dimension)2-(LV systolic 
dimension)2 /(LV end-diastolic dimension)2 when the wall 
motion was normal. LV mass index was estimated by its 
dimension and wall thickness according to the method of 
Devereux and associates (1986). To determine the ratio of 
E to A velocity and deceleration time, a 4 × 4 mm sample 
volume was placed at the tips of the mitral leaﬂ  ets and the 
transmitral pulsed Doppler waves were recorded at three 
consecutive cardiac cycles.
Endpoint
The participants were monitored regularly for occurrence of 
the cardiovascular events by examining the clinical records 
and ﬁ  les. The cardiovascular events were sudden death, heart 
failure, unstable angina pectoris, myocardial infarction, and Vascular Health and Risk Management 2007:3(4) 419
BNP and CRP in type 2 diabetic patients
stroke. The criteria used to diagnose the cardiovascular events 
are as follows: heart failure, according to Framingham Heart 
Study congestive heart failure criteria (Margolis et al 1974); 
acute myocardial infarction, typical electrocardiographic 
changes and elevated cardiac enzyme levels; stroke, a neu-
rological deﬁ  cit with sudden or rapid onset that persisted 
for 24 hours or longer. The diagnosis of angina pectoris was 
conﬁ  rmed by coronary angiography showing atherosclerotic 
narrowing of coronary arteries. 
Statistical analysis
Data were expressed as mean ± SD or median with 25 and 75 
percentiles. Unadjusted and adjusted association of BNP or 
CRP with the other variables was evaluated using Spearman’s 
correlation coefﬁ  cient and linear regression, respectively. For 
adjusted association, a model with parameters signiﬁ  cantly 
correlated by the unadjusted association was ﬁ  tted, and then 
the other variables were added to see if there was signiﬁ  cant 
residual association. A Cox proportional hazards model was 
used to test the signiﬁ  cance of any variables as predictors of 
the cardiovascular events in the study subjects. The covariates 
included in this model were history of cardiovascular events, 
age, gender, current smoking, body mass index, HOMA-R 
index, systolic blood pressure, total cholesterol, serum creati-
nine, urinary albumin, BNP, CRP, LV ejection fraction and 
medicines, such as angiotensin converting enzyme inhibitor, 
angiotensin II type 1 receptor blocker, β-blocker, aspirin, 
thiazolidinedione, and statin. Results are presented as rela-
tive risks with 95% conﬁ  dence intervals. Receiver-operating 
characteristic (ROC) curves were constructed to examine the 
predictive values of plasma BNP and CRP concentrations for 
the cardiovascular events. SPSS version 11.0 (SPSS Japan, 
Tokyo, Japan) was used for all the analyses, and statistical 
signiﬁ  cance was accepted at p < 0.05. 
Results
Patients’ characteristics
Baseline of the clinical characteristics and echocardio-
graphic parameters of the study participants are shown in 
Tables 1 and 2, respectively. Plasma BNP level was distrib-
uted between 1.8 and 526.6 pg/mL, and 15.6% of the patients 
exceeded 100 pg/mL. Plasma CRP level was distributed 
between 0.00 and 2.17 mg/dL, and 39% of those exceeded 
0.1 mg/dL. Twenty eight percent of patients had received 
angiotensin converting enzyme inhibitor or angiotensin II 
type 1 receptor blocker. By echocardiogram, only 1.9% of 
patients had LV ejection fractions less than 40%. Table 3 
shows the variables considered as potentially associated with 
BNP or CRP. Several parameters, such as age, HOMA-R, 
creatinine, LA size, LV mass index, and LV ejection fraction 
were associated with BNP. CRP was associated with meta-
bolic parameters, such as BMI, HOMA-R and HDL-C level 
as well as urinary albumin, LA size, and EV ejection fraction. 
As shown in Table 4, BNP was independently associated with 
LA size, LV ejection fraction, gender, urinary albumin, serum 
Table 1 Clinical characteristics of the patients (n = 109)
Parameter 
Age, y  71 ± 10
Male (%)  50
Body mass index (kg/m2) 24  ± 4
Current smoker (%)  17
Hypertension (%)  77
Hyperlipidemia (%)  53
Atrial ﬁ  brillation (%)  6
Valvular diseases (%)  10
History of cardiovascular diesases (N/C/H)  80/13/16
Systolic blood pressure (mmHg)  137 ± 16
Diastolic blood pressure (mmHg)  71 ± 11
Fasting blood glucose (mg/dL)  137 ± 44
Hemoglobin A1c (%)  6.6 ± 1.5
Total cholesterol (mg/dL)  204 ± 35
Triglyceride (mg/dL)  113 [86, 158]
Serum creatinine (mg/dL)  0.8 ± 0.3
Urinary albumin (mg/gCreatinine)  33 [13, 139]
BNP (pg/mL)  26.7 [14.3, 57.2]
CRP (mg/dL)  0.10 [0.04, 0.20]
Sulfonylurea (%)  48
Biguanide (%)  3
α-glycosidase inhibitor (%)  34
thiazolidinedione (%)  6
Glinide (%)  8
ACEI (%)  17
ARB (%)  11
β-blocker (%)  16
Calcium channel blocker (%)  55
Diuretics (%)  9
Aspirin (%)  13
Statin (%)  24
Notes: Data are presented as means ± SD, percentage or median [25, 75 percen-
tiles] of the values. 
Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin 
II type 1 receptor blocker; N, C and H indicates none of any past cardiovascular 
diseases, cerebral infarction/hemorrhage or heart diseases, such as angina pectoris, 
myocardial infarction and heart failure.
Table 2 Echocardiographic parameters
Size of left atrium (cm)   3.2 ± 0.7
Left ventricular diastolic dimension (cm)   4.2 ± 0.8
Left ventricular systolic dimension (cm)   2.7 ± 0.6
Left ventricular mass (g/m2) 132  ± 46
Left ventricular ejection fraction (%)     66 ± 10
Ratio of E to A velocity   0.9 ± 0.5
Deceleration time (ms)   211 ± 63
Values are means ± SDVascular Health and Risk Management 2007:3(4) 420
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creatinine, and BMI. Meanwhile, CRP was independently 
associated with LV ejection fraction and HDL-C. 
Occurrence of cardiovascular events
During the average follow-up period of 30 months (range, 
3 to 37), 15 patients (14%) had cardiovascular events. Five 
patients had the ﬁ  rst events of unstable angina pectoris in 1, 
acute myocardial infarction in 2, and congestive heart failure 
in 2. Ten patients had recurrences: sudden death in 1 and 
ventricular ﬁ  brillation in 1, and hospitaization due to conges-
tive heart failure in 4, cerebral infarction in 3 and unstable 
angina pectoris in 1.
Univariate and multivariate regression 
analyses
Table 5 shows the results of univariate and multivariate 
Cox regression analyses using step-wise variable selection. 
In univariate regression analysis, the history of the cardio-
vascular events, BNP, LV ejection fraction, use of ACE 
inhibitor, serum creatinine, and CRP level were extracted 
as signiﬁ  cant factors for the events during the follow-up 
period. In multivariate analysis, the history and BNP re-
mained independent.
Identiﬁ  cation of subgroups of patients 
with high risk of events
Figure 1 shows the sensitivity and specificity of various 
cut-off points of BNP or CRP for predicting the cardiovas-
cular events by ROC curves. On each curve, the potential 
optimal point was indicated. According to the basis on 
the optimal values of BNP and CRP, the patients were 
divided into four categories; group I, BNP 53 pg/mL 
and CRP 0.095 mg/dL; group II, BNP 53 pg/mL and 
CRP 0.095 mg/dL; group III, BNP53 pg/mL and CRP 
0.095 mg/dL; group IV, BNP 53 pg/mL and CRP  
0.095 mg/dL. With this combination, patients with BNP 
53 pg/mL and CRP 0.095 mg/dL had the highest 
incidence of cardiovascular event among the respective 
groups (Figure 2). 
Discussion
Once patients with diabetes mellitus develop clinically overt 
coronary artery disease, their prognosis is particularly poor 
irrespective of the control of blood glucose levels (UK Prospec-
tive Diabetes Study Group 1998; Howard et al 2006). As the 
prevalence of underlying coronary artery disease, stroke and 
heart failure in diabetic patients is higher than in the non-dia-
betic population (Sprafka et al 1991), screening and assessment 
of cardiovascular risk in diabetic patients are of importance.
Table 3  Association of BNP or CRP with the other variables
 BNP    CRP
  Spearman CC  p value  Spearman CC  p value
Age 0.445    <0.001  0.049    0.61
BMI  –0.079   0.411  0.370   <0.001
HOMA-R  –0.206   0.033  0.254   0.008
HDL-C –0.136    0.158  –0.260  0.006
Urinary
albumin 0.130    0.18  0.224  0.02
Creatinine 0.306    0.001  0.119    0.219
LA size  0.268   0.006  0.206   0.038
LV mass
index 0.330    0.001  0.121  0.23
LVEF –0.231    0.018  –0.212  0.031
Abbreviations: CC, correlation coefﬁ  cient; BMI, body mass index; HOMA, homeo-
stasis model assessment; LA, left atrial; LV, left ventricular; EF, ejection fraction.
Table 4 Linear regression analysis for BNP and CRP
Dependent Independent  Regression  p  value
variable varible  coefﬁ  cient 
BNP LA  size  0.321  <0.001
 LVEF –0.282  0.001
 Gender  0.334  0.001
 Urinary  albumin  2.875  0.005
 Serum  creatinine  2.751  0.007
 BMI –0.179  0.037
CRP LVEF  –3.338  0.001
 HDL-C  –2.682  0.009
Note: For BNP, age, gender, body mass index (BMI), urinary albumin, serum creati-
nine, left atrial (LA) size, left ventricular ejection fraction (LVEF), LV mass index and 
CRP were included as the independent variables. For CRP, age, BMI, homeostasis 
model assessment (HOMA)-R, plasma levels for total cholesterol, triglyceride, 
HDL-C and LVEF were included as independent variables. 
Table 5 Univariate and multivariate cox regression analysis
   Univariate  Multivariate
Variables  HR  95% CI    HR  95% CI
Past event  8.535  2.997–24.32  <0.001  4.819    1.299–17.881  0.019
BNP
(10 pg/mL)  1.008  1.005–1.011  <0.001  1.007      1.002–1.012  0.01
LVEF (%)  0.92  0.881–0.960  <0.001     
ACEI use  0.201  0.077–0.522  <0.001     
Creatinine
(mg/dL) 7.846  2.723–22.60  <0.001     
CRP
(0.1 mg/dL)  3.002  1.416–6.364  0.004     
Note: Univariate and multivariate models were constructed by Cox regression 
with forward step wise variable selection. Covariates included in the analysis 
were as follows: age, gender, body mass index, history of past cardiovascular event, 
hypertension, hyperlipidemia, fast blood sugar, HbA1c, urinary albumin, BNP, serum 
creatinine, CRP and LV ejection fraction (LVEF), LV mass index, use of angioten-
sin converting enzyme inhibitor (ACEI), angiotensin II type 1 receptor blocker, 
β-blocker, statin, thiazolidinedione and/or aspirin. Hazard ratios (HR) are for an 
increment in the unit or number shown in parenthesis.Vascular Health and Risk Management 2007:3(4) 421
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Firstly, this study shows the signiﬁ  cance of understanding 
medical history in the diabetic patients, as those with a past 
event had a high incidence of recurrence. Indeed, it was the 
strongest independent factor for predicting the events during 
the follow-up period. In patients enrolled, 5.6% developed 
the ﬁ  rst event, while 34% for the recurrence. It seems that 
these patients had a high occurrence of cardiovascular events 
in this study. These results are reported to be dependent on 
the study population, with the range between 10%–22% 
during patient follow-up (Booth et al 2006; Yoshimura et al 
2006; Wilcox et al 2007). It is of note that cardiovascular 
event increases up to 50% in those who had suffered from 
myocardial infarction (Murcia et al 2004). Age is also strong 
risk factor for cardiovascular disease in people with diabetes, 
especially in those that have a history of myocardial infarc-
tion (Booth et al 2006). Blockade of angiotensin II with the 
angiotensin converting enzyme inhibitor or angiotensin II 
type 1 receptor blocker seems to be beneﬁ  cial among patients 
with diabetes mellitus in reducing subsequent risks of cardio-
vascular events. However this was not frequently within this 
study. Thus, our data demonstrates that elderly patients with 
diabetes mellitus are inclined to experience cardiovascular 
events. In order to decrease the likelihood of future events, 
more accurate diagnostic tools to assess the risk and intensive 
medical treatments would be necessary.
Secondly, this data is evidence that the plasma level of 
BNP was useful parameter to predict the future event in 
diabetic patients. The increased level of plasma BNP was 
associated with enlarged size in LA and reduced systolic 
function in LV. This supports the notion that the structural 
or functional changes of heart are important determinants for 
BNP production (Maeda et al 1998; de Lemos et al 2001). 
  According to Dawson and colleagues (2005), increased 
plasma BNP concentration is associated with cardiovascu-
lar risk even in subjects with mean BNP levels lower than 
30 pg/mL, who had normal LV systolic functions and no 
history of coronary heart disease. Epsteyn and colleagues 
(2003) report the extended utility of BNP measurement for 
screening the latent LV dysfunction in patients with diabetes 
mellitus. On the other hand, CRP has been recognized as a 
factor closely associated with the development of cardio-
vascular diseases (Ridker et al 2000; Danesh et al 2004; 
Wakugawa et al 2006) and in line with this, high CRP levels 
indicate an increased risk of cardiovascular events among 
men with type 2 diabetes mellitus (Schulze et al. 2004). 
Meanwhile, Howard and colleagues (2006) reported that the 
risk of cardiovascular events in diabetic patients depends on 
concomitant metabolic disorders. In line with the previous 
studies (Shah et al 2006; Zuliani et al 2007), our data showed 
that the plasma level of CRP was independently associated 
with low HDL-C and LV ejection.
As BNP levels were independently affected by age, 
gender and renal function, clinical settings to screen the 
LV dysfunction might be limited. In addition, BNP levels 
1.00 .75 .50 .25 0
1.00
.75
.50
.25
0
1.00
.75
.50
.25
0
1.00 .75 .50 .25 0
S
e
n
s
i
t
i
v
i
t
y
1-Specificity
S
e
n
s
i
t
i
v
i
t
y
1-Specificity
A B
53 pg/mL
0.095 mg/dL
AUC=0.750 AUC=0.740
Figure 1 ROC curves and the sensitivity/speciﬁ  city of BNP (A) or CRP (B) level for predicting the cardiovascular events in diabetic patients. Areas under the ROC curve 
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are believed to increase with thiazolidinedione treatment 
(Ogawa et al 2003), however the medication had little inﬂ  u-
ence on the predictive value of BNP in this study (data not 
shown). On the other hand, CRP is not disease-speciﬁ  c, and 
its concentration might elevate as a consequence of infection, 
inﬂ  ammation and undeﬁ  ned reasons as well as atheroscle-
rosis-related risk factors (Miller et al 2007). At this point, it 
remains to be elucidated whether measurement of CRP can 
be useful in general clinical practice to evaluate the risk of 
cardiovascular diseases. Regardless of these limitations, this 
study shows that elevation in the plasma levels of either BNP 
or CRP revealed the higher incidence of morbidity, compared 
with the patient category with low concentration of both 
markers. Importantly, patients categorized into both high-
BNP and -CRP levels demonstrated the highest incidence in 
the cardiovascular event. Our ﬁ  ndings are supported by two 
studies in which the combined measurements of N-terminal 
proBNP (or BNP) and CRP have been reported to provide 
an additive predictive value in patients with stable coronary 
heart disease (Ndrepepa et al 2006) and dilated cardiomyopa-
thy (Ishikawa et al 2006). Taken together, this data supports 
and extends the hypothesis that elevated BNP and CRP levels 
reﬂ  ect an increased risk of cardiovascular events. Therefore 
the combined use of BNP and CRP measurements would 
provide better identiﬁ  cation of cardiovascular risk in patients 
with type 2 diabetes mellitus, compared with the use of each 
alone. BNP levels may reﬂ  ect alterations in cardiac structure 
and function, while CRP might be associated with subtle 
vascular inﬂ  ammation. A number of studies have shown the 
utility of BNP and CRP as diagnostic markers for screening 
cardiovascular risk to recognize the disease progression and 
to see the effect of medical treatment. However, the informa-
tion is still too limited to use BNP and CRP as diagnostic 
markers regularly, for example to measure the levels of blood 
sugar and HbA1c, in diabetic patients. Further studies are 
necessary to determine whether BNP and CRP levels are 
useful for monitoring the occult cardiac dysfunction and 
vascular inﬂ  ammation in general clinical practice.
This was an observation study in which a small number 
of participants were examined, and the hypothesis raised in 
this study may need to be tested in a larger number of patients 
with longer study periods. Also, because the average age was 
greater than seventy years, we did not assess the physical 
activity/daily exercise, which has been reported to be associ-
ated with mortality in men with diabetes mellitus (Wei et al 
2000). Furthermore, threshold values obtained from the ROC 
curves are dependent on the study population, and might have 
a different optimal point in another set of patients. 
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